$607 Million is the total value of NEXTHERA CAPITAL LP's 40 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
VTGN | Exit | VistaGen Therapeutics Inc | $0 | – | -138,132 | -100.0% | -0.03% | – |
TGTX | Exit | TG Therapeutics Inc | $0 | – | -30,000 | -100.0% | -0.04% | – |
KALV | Exit | KalVista Pharmaceuticals Inc | $0 | – | -180,794 | -100.0% | -0.32% | – |
ANIP | Exit | ANI Pharmaceuticals Inc | $0 | – | -41,905 | -100.0% | -0.50% | – |
TXMD | Exit | TherapeuticsMD Inc | $0 | – | -528,351 | -100.0% | -0.59% | – |
OTIC | Exit | Otonomy Inc | $0 | – | -602,748 | -100.0% | -0.62% | – |
CTMX | Exit | CytomX Therapeutics Inc | $0 | – | -179,870 | -100.0% | -0.70% | – |
TSRO | Exit | TESARO Incput | $0 | – | -50,000 | -100.0% | -0.76% | – |
AVDL | Exit | Avadel Pharmaceuticals PLCsponsored adr | $0 | – | -505,921 | -100.0% | -0.76% | – |
SPPI | Exit | Spectrum Pharmaceuticals Incput | $0 | – | -259,300 | -100.0% | -0.91% | – |
ATRA | Exit | Atara Biotherapeutics Inc | $0 | – | -286,647 | -100.0% | -0.96% | – |
MRNS | Exit | Marinus Pharmaceuticals Inc | $0 | – | -925,327 | -100.0% | -1.39% | – |
GLYC | Exit | GlycoMimetics Inc | $0 | – | -480,442 | -100.0% | -1.49% | – |
ALXN | Exit | Alexion Pharmaceuticals Inccall | $0 | – | -72,400 | -100.0% | -1.60% | – |
SCMP | Exit | Sucampo Pharmaceuticals Inccl a | $0 | – | -510,486 | -100.0% | -1.69% | – |
ALNY | Exit | Alnylam Pharmaceuticals Inc | $0 | – | -86,293 | -100.0% | -2.02% | – |
FLXN | Exit | Flexion Therapeutics Inccall | $0 | – | -466,500 | -100.0% | -2.15% | – |
ABLX | Exit | Ablynx NVsponsored adr | $0 | – | -637,884 | -100.0% | -2.94% | – |
AZN | Exit | AstraZeneca PLCcall | $0 | – | -466,600 | -100.0% | -2.98% | – |
BMY | Exit | Bristol-Myers Squibb Cocall | $0 | – | -295,600 | -100.0% | -3.34% | – |
MRK | Exit | Merck & Co Inc | $0 | – | -346,293 | -100.0% | -3.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Insmed Inc | 13 | Q2 2019 | 10.0% |
Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
Shire PLC | 9 | Q1 2018 | 13.6% |
Immunomedics Inc | 9 | Q2 2019 | 7.8% |
Allergan PLC | 8 | Q2 2019 | 7.6% |
FibroGen Inc | 8 | Q3 2018 | 3.0% |
Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
Pfizer Inc | 7 | Q2 2017 | 19.1% |
Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2019-08-14 |
13F-HR | 2019-05-15 |
13F-HR | 2019-02-14 |
SC 13G/A | 2019-02-14 |
SC 13G/A | 2019-02-14 |
SC 13G/A | 2019-02-14 |
SC 13G | 2018-11-26 |
13F-HR | 2018-11-14 |
13F-HR | 2018-08-14 |
SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.